The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States ...

Zepbound (tirzepatide) is an FDA-approved medication for weight management. People need a prescription to buy this medication, and several telemedicine companies offer doctor-led prescription and ...

Zepbound (tirzepatide) can cause side effects that range from mild to serious. More common side effects include nausea, diarrhea, and constipation. If side effects from Zepbound become hard to ...

Zepbound (tirzepatide) is a prescription drug used to help with weight loss and sleep apnea in certain adults. The drug comes as a liquid solution inside vials or prefilled injection pens. It’s ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly LLY-0.27%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Yet federal regulators recently declared the blockbuster weight-loss drugs Wegovy and Zepbound are no longer in shortage. That means consumers who use telehealth companies or medical spas to get ...

INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the ...

Eli Lilly & Co. is ramping up the fight against cheaper, copycat versions of Zepbound by lowering prices for a version of its blockbuster obesity drug. The company is reducing the cost of its 2.5 ...